186 human secreted proteins

• US 6,420,526 B1
• Filed: 09/08/1998
• Issued: 07/16/2002
• Est. Priority Date: 03/07/1997
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GSK plc)
• Original Assignee: Human Genome Sciences Incorporated (GSK plc)
• Inventors: Zeng, Zhizhen, Soppet, Daniel P., Bednarik, Daniel R., Li, Yi, Yu, Guo-Liang, Ferrie, Ann M., Ni, Jian, Rosen, Craig A., Carter, Kenneth C., Ebner, Reinhard, Ruben, Steven M., Endress, Gregory A., Moore, Paul A., Young, Paul E., Shi, Yanggu, Brewer, Laurie A., Duan, Roxanne, Olsen, Henrik S., Feng, Ping, Hu, Jing-Shan, Kyaw, Hla, Fischer, Carrie L., Florence, Kimberly A., Greene, John M., Lafleur, David W.
• Primary Examiner(s): Brusca, John S.
• Assistant Examiner(s): KIM, YOUNG J
• Application Number:
  US09/149,476
• Time in Patent Office: 1,407 Days
• Field of Search: 435/6, 435/183, 536/23.1, 530/350
• US Class Current: 530/350
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Claims

1. An isolated protein comprising amino acid residues 27 to 234 of SEQ ID NO:

478.

2. The isolated protein of claim 1 which comprises amino acid residues 2 to 234 of SEQ ID NO:

478.

3. The isolated protein of claim 1 which comprises amino acid residues 1 to 234 of SEQ ID NO:

478.

4. The protein of claim 1 which comprises a heterologous polypeptide sequence.

5. A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

6. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 1 by a cell; and

(b) recovering said protein.

51. The protein of claim 4, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

7. An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

8. The isolated protein of claim 7 which comprises the amino acid sequence of the complete polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903, excepting the N-terminal methionine.

9. The isolated protein of claim 7 which comprises the amino acid sequence of the complete polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

10. The protein of claim 7 which comprises a heterologous polypeptide sequence.

11. A composition comprising the protein of claim 7 and a pharmaceutically acceptable carrier.

12. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 7 by a cell; and

(b) recovering said protein.

52. The protein of claim 10, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

13. An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 27 to 234 of SEQ ID NO:

478.

14. The isolated protein of claim 13 wherein said polypeptide sequence is at least 90% identical to amino acid residues 1 to 234 of SEQ ID NO:

478.

15. The isolated protein of claim 13 wherein said polypeptide sequence is at least 95% identical to amino acid residues 27 to 234 of SEQ ID NO:

478.

16. The isolated protein of claim 13 wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 234 of SEQ ID NO:

478.

17. The protein of claim 13 which comprises a heterologous polypeptide sequence.

18. A composition comprising the protein of claim 13 and a pharmaceutically acceptable carrier.

19. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 13 by a cell; and

(b) recovering said protein.

53. The protein of claim 17, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

20. An isolated protein comprising a polypeptide sequence which is at least 90% identical to the secreted portion of the polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

21. The isolated protein of claim 20 wherein saod polypeptide sequence is at least 95% identical to the secreted portion of the polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

22. The protein of claim 20 which comprises a heterologous polypeptide sequence.

23. A composition comprising the protein of claim 20 and a pharmaceutically acceptable carrier.

24. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 20 by a cell; and

(b) recovering said protein.

54. The protein of claim 22, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

25. An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 27 to 234 of SEQ ID NO:

478.

26. The isolated protein of claim 25 which comprises at least 50 contiguous amino acid residues of amino acid residues 27 to 234 of SEQ ID NO:

478.

27. The protein of claim 25 which comprises a heterologous polypeptide sequence.

28. A composition comprising the protein of claim 25 and a pharmaceutically acceptable carrier.

29. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 25 by a cell; and

(b) recovering said protein.

55. The protein of claim 27, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

30. An isolated protein comprising at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

31. The isolated protein of claim 30 which comprises at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

32. The protein of claim 30 which comprises a heterologous polypeptide sequence.

33. A composition comprising the protein of claim 30 and pharmaceutically acceptable carrier.

34. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 30 by a cell; and

(b) recovering said protein.

56. The protein of claim 32, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

35. An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 234 of SEQ ID NO:

478.

36. The isolated protein of claim 35 which comprises at least 50 contiguous amino acid residues of amino acid residues 1 to 234 of SEQ ID NO:

478.

37. The protein of claim 35 which comprises a heterologous polypeptide sequence.

38. A composition comprising the protein of claim 35 and a pharmaceutically acceptable carrier.

39. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 35 by a cell; and

(b) recovering said protein.

57. The protein of claim 37, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

40. An isolated protein comprising at least 30 contiguous amino acid residues of the complete polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

41. The isolated protein of claim 40 which comprises at least 50 contiguous amino acid residues of the complete polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

42. The protein of claim 40 which comprises a heterologous polypeptide sequence.

43. A composition comprising the protein of claim 40 and pharmaceutically acceptable carrier.

44. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 40 by a cell; and

(b) recovering said protein.

58. The protein of claim 42, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

45. An isolated protein comprising a polypeptide sequence which is at least 90% identical to the complete polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

46. The isolated protein of claim 45, wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HNFIP24 cDNA contained in ATCC Deposit No. 97903.

47. The protein of claim 45 which comprises a heterologous polypeptide sequence.

48. The protein of claim 47, wherein said heterologous polypeptide sequence is the Fc domain of immunoglobulin.

49. A composition comprising the protein of claim 45 and a pharmaceutically acceptable carrier.

50. An isolated protein produced by a method comprising:

(a) expressing the protein of claim 45 by a cell; and

(b) recovering said protein.